Mamta Parikh

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 21 papers. Top paper: “Effect of Cisplatin and Gemcitabine With or Without Berzosertib in Patients With Advanced Urothelial Carcinoma”.

Effect of Cisplatin and Gemcitabine With or Without Berzosertib in Patients With Advanced Urothelial Carcinoma

JAMA Oncology(2021)10.1001/jamaoncol.2021.3441

N/A

1.6DataRank · unranked

45 citations

Paul Frankel, Amir Mortazavi, Matthew I. Milowsky, Ulka N. Vaishampayan, Mamta Parikh +15 more

A phase 2 study of berzosertib (M6620) in combination with carboplatin compared with docetaxel in combination with carboplatin in metastatic castration-resistant prostate cancer.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.5034

N/A

0.461DataRank · unranked

8 citations

Wanling Xie, Edmund Folefac, Daniel Lee, Mamta Parikh, David J. Einstein +12 more

Markers of bone metabolism and overall survival in men with bone-metastatic hormone sensitive prostate cancer (HSPC): A subset analysis of SWOG S1216, a phase III trial of androgen deprivation with or without orteronel

Prostate Cancer and Prostatic Diseases(2024)10.1038/s41391-024-00813-3

N/A

0.241DataRank · unranked

4 citations

Edward Mayerson, Erik Gertz, Catherine M. Tangen, Amir Goldkorn, Marta Van Loan +10 more

A randomized phase II study comparing cisplatin and gemcitabine with or without berzosertib in patients with advanced urothelial carcinoma.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.4507

N/A

0DataRank · unranked

1 citations

Amir Mortazavi, Matthew I. Milowsky, Ulka N. Vaishampayan, Mamta Parikh, Yung Lyou +15 more

A phase I trial of elimusertib in combination with cisplatin or with cisplatin plus gemcitabine in advanced solid tumors with an emphasis on urothelial carcinoma.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.tps3174

N/A

0DataRank · unranked

5 citations

Paul Frankel, Jan H. Beumer, Naoko Takebe, Ming Yin, Hamid Emamekhoo +4 more

Bone biomarkers and overall survival (OS) in men with advanced hormone-sensitive prostate cancer (HSPC): Results from SWOG S1216, a phase III trial of ADT +/- orteronel.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.5071

N/A

0DataRank · unranked

2 citations

Edward Mayerson, Erik Gertz, Catherine M. Tangen, Amir Goldkorn, Marta Van Loan +10 more

Prostate cancer and bone: clinical presentation and molecular mechanisms

Endocrine Related Cancer(2023)10.1530/erc-22-0360

N/A

0DataRank · unranked

14 citations

Margaret Li Krackeler, Maitreyee K. Jathal, Mamta Parikh, P. Ghosh, J. Kent Leach +2 more

Cisplatin-induced increase in heregulin 1 and its attenuation by the monoclonal ErbB3 antibody seribantumab in bladder cancer

Scientific Reports(2023)10.1038/s41598-023-36774-1

N/A

0DataRank · unranked

11 citations

Maria Malvina Tsamouri, Salma Siddiqui, Christopher A. Lucchesi, Demitria M. Vasilatis, Benjamin A. Mooso +8 more

Bone Biomarkers and Subsequent Survival in Men with Hormone-sensitive Prostate Cancer: Results from the SWOG S1216 Phase 3 Trial of Androgen Deprivation Therapy with or Without Orteronel

European Urology(2023)10.1016/j.eururo.2023.03.036

N/A

0DataRank · unranked

10 citations

Edward Mayerson, Erik Gertz, Catherine M. Tangen, Amir Goldkorn, Marta Van Loan +11 more

A phase 2 study of the WEE1 inhibitor AZD1775 in SETD2-deficient advanced solid tumor malignancies.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.3104

N/A

0DataRank · unranked

3 citations

W. Kimryn Rathmell, Geoffrey I. Shapiro, Jordi Rodon Ahnert, Devalingam Mahalingam, Nikolaos A. Trikalinos +9 more

A phase II study of olaparib (AZD2281) in patients (Pts) with metastatic/advanced urothelial carcinoma and other genitourinary (GU) tumors with DNA-repair defects.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.tps4607

N/A

0DataRank · unranked

3 citations

Nicholas I. Simon, Scot A. Niglio, Lisa Ley, Lisa M. Cordes, Rouf Banday +15 more

Prostate-specific antigen value at 3 & 7 months (PSA-3mo, PSA-7mo) and overall survival (OS) in metastatic hormone-sensitive prostate cancer (mHSPC) treated with androgen deprivation (ADT) with or without orteronel (SWOG S1216).

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.5074

N/A

0DataRank · unranked

2 citations

Catherine M. Tangen, Maha Hussain, Shilpa Gupta, Yeonjung Jo, Andrea Harzstark +15 more

A phase 1/2 study of combination olaparib and radium-223 in men with metastatic castration-resistant prostate cancer with bone metastases (COMRADE): A trial in progress.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.tps5110

N/A

0DataRank · unranked

2 citations

Wanling Xie, Archana Ajmera, Arlene Araneta, Christina Jamieson, Edmund Folefac +14 more

Bone biomarkers and subsequent survival in men with bone-metastatic hormone sensitive prostate cancer (HSPC): Results from the phase III SWOG S1216 trial of androgen deprivation +/- orteronel.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.5048

N/A

0DataRank · unranked

0 citations

Edward Mayerson, Erik Gertz, Catherine M. Tangen, Amir Goldkorn, Marta Van Loan +10 more

Three- and Seven-month Prostate-specific Antigen Levels as Prognostic Markers for Overall Survival in Metastatic Hormone-sensitive Prostate Cancer: Results from SWOG S1216, a Phase 3 Randomized Trial of Androgen Deprivation Plus Orteronel or Bicalutamide

European Urology Oncology(2024)10.1016/j.euo.2024.03.001

N/A

0DataRank · unranked

9 citations

Catherine M. Tangen, Maha Hussain, Shilpa Gupta, Sam Callis, Yeonjung Jo +17 more

The ATR Inhibitor Elimusertib in Combination with Cisplatin in Patients with Advanced Solid Tumors: A California Cancer Consortium Phase I Trial (NCI 10404)

Cancer Research Communications(2025)10.1158/2767-9764.crc-25-0305

N/A

0DataRank · unranked

1 citations

Nataliya V. Uboha, Naoko Takebe, Kit Tam, Philippe L. Bédard, Kari B. Wisinski +13 more

AREN1721, a randomized phase 2 trial of axitinib+nivolumab combination therapy vs. single agent nivolumab for the treatment of TFE/translocation renal cell carcinoma (tRCC) across all age groups, an NCI National Clinical Trials Network (NCTN) phase 2 study.

Journal of Clinical Oncology(2025)10.1200/jco.2025.43.16_suppl.4521

N/A

0DataRank · unranked

7 citations

Lindsay A. Renfro, Matthew R. Zibelman, Ana M. Molina, Mamta Parikh, Luke Pater +8 more

A phase II study of M6620 in combination with carboplatin compared with docetaxel in combination with carboplatin in metastatic castration-resistant prostate cancer.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.tps5597

N/A

0DataRank · unranked

3 citations

Wanling Xie, Mamta Parikh, Daniel Lee, Elizabeth R. Kessler, David J. Einstein +8 more

Academic research careers for medical doctors (ARC-MD): a five-year UC Davis training program to foster the next generation of physician-scientists

Medical Education Online(2025)10.1080/10872981.2025.2568575

N/A

0DataRank · unranked

0 citations

Jennifer L. Rosenthal, Luis F. Santana, Frederick J. Meyers, Mamta Parikh

A phase II study of M6620 in combination with carboplatin compared with docetaxel in combination with carboplatin in metastatic castration-resistant prostate cancer.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.6_suppl.tps252

N/A

0DataRank · unranked

0 citations

Wanling Xie, Mamta Parikh, Daniel Lee, Elizabeth R. Kessler, David J. Einstein +8 more

Phase Ib trial of reformulated niclosamide with abiraterone/prednisone in men with castration-resistant prostate cancer

Scientific Reports(2021)10.1038/s41598-021-85969-x

N/A

0DataRank · unranked

85 citations

Chengfei Liu, Chun‐Yi Wu, Christopher P. Evans, Marc Dall’Era, Daniel Robles +5 more